Skip to main content Accessibility help
×
Home

Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression

  • Mu-Hong Chen (a1) (a2) (a3), Wei-Chen Lin (a1) (a2) (a3), Hui-Ju Wu (a2), Ya-Mei Bai (a1) (a2), Cheng-Ta Li (a1) (a2) (a3), Shih-Jen Tsai (a1) (a2) (a3), Chen-Jee Hong (a1) (a2) (a3), Pei-Chi Tu (a1) (a2) (a4), Chih-Ming Cheng (a1) (a2) (a3) and Tung-Ping Su (a1) (a2) (a4) (a3) (a5)...

Abstract

Background.

The antidepressant effect of low-dose ketamine infusion on Taiwanese patients with anxious vs nonanxious treatment-resistant depression (ANX-TRD vs NANX-TRD) has remained unknown.

Methods.

In total, 71 patients with TRD were randomized to three groups. Each group had participants who received saline infusions mixed with 0 (a normal saline infusion), 0.2, and 0.5 mg/kg of ketamine. Participants were followed up for 2 weeks. Anxious depression was defined as major depressive disorder with a total score of 7 or more on the 17-item Hamilton Depression Rating Scale Anxiety-Somatization factor. Generalized estimating equation models were used to investigate the effects of treatment (ketamine vs placebo) and depression type (ANX-TRD vs NANX-TRD) in the reduction of depressive symptoms during the follow-up period.

Results.

Patients with ANX-TRD were less likely to respond to a single low-dose ketamine infusion than those with NANX-TRD. Among patients with NANX-TRD, low-dose ketamine infusion was significantly superior to placebo for reducing depressive symptoms. However, among patients with ANX-TRD, ketamine was not superior to placebo; nonetheless, approximately 30% of the patients responded to ketamine infusion compared to 13% who responded to the placebo.

Conclusions.

Low-dose ketamine infusion was effective for Taiwanese patients with NANX-TRD but not so effective for those with ANX-TRD. A higher level of anxiety severity accompanying depression was related to greater depression severity. This may confound and reduce the antidepressant effect of ketamine infusion.

Copyright

Corresponding author

Tung-Ping Su Email: tomsu0402@gmail.com

References

Hide All
1.Fava, M, Rush, AJ, Alpert, JE, et al.Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342351.
2.Gaspersz, R, Nawijn, L, Lamers, F, Penninx, B. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31(1):1725.
3.Fava, M, Alpert, JE, Carmin, CN, et al.Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34(7):12991308.
4.Braund, TA, Palmer, DM, Williams, LM, Harris, AWF. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report. Psychol Med. 2019 Apr 26:111. doi:10.1017/S0033291719000941
5.Braund, TA, Palmer, DM, Williams, LM, Harris, AW. Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: an iSPOT-D report. Aust N Z J Psychiatry. 2019;58(8):782793.
6.Wiethoff, K, Bauer, M, Baghai, TC, et al.Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. J Clin Psychiatry. 2010;71(8):10471054.
7.Murrough, JW, Iosifescu, DV, Chang, LC, et al.Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):11341142.
8.Su, TP, Chen, MH, Li, CT, et al.Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42(13):24822492.
9.Salloum, NC, Fava, M, Freeman, MP, et al.Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression Anxiety. 2019;36(3):235243.
10.Ionescu, DF, Luckenbaugh, DA, Niciu, MJ, et al.Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):e932e938.
11.Ionescu, DF, Luckenbaugh, DA, Niciu, MJ, Richards, EM, Zarate, CA. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord . 2015;17(4):438443.
12.Li, CT, Chen, MH, Lin, WC, et al.The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp. 2016;37(3):10801090.
13.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:5662.
14.Montgomery, SA, Rani, SJ, McAuley, R, Roy, D, Montgomery, DB. The antidepressant efficacy of zimelidine and maprotiline. Acta Psychiatr Scand Suppl. 1981;290:219224.
15.Cleary, P, Guy, W. Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res. 1977;(1):115120.
16.Jakubovski, E, Bloch, MH. Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry. 2014;75(7):738747.
17.Clarke, E, Clarke, P, Gill, S, Paterson, T, Hahn, L, Galletly, C. Efficacy of repetitive transcranial magnetic stimulation in the treatment of depression with comorbid anxiety disorders. J Affect Disord. 2019;252:435439.
18.Su, TP, Huang, CC, Wei, IH. Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. J Clin Psychiatry. 2005;66(7):930937.
19.Glue, P, Medlicott, NJ, Harland, S, et al.Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017;31(10):13021305.
20.Taylor, JH, Landeros-Weisenberger, A, Coughlin, C, et al.Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology. 2018;43(2):325333.
21.Feder, A, Parides, MK, Murrough, JW, et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA psychiatry. 2014;71(6):681688.
22.Frye, MA, Blier, P, Tye, SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334336.

Keywords

Type Description Title
WORD
Supplementary materials

Chen et al. Supplementary Materials
Chen et al. Supplementary Materials

 Word (33 KB)
33 KB

Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression

  • Mu-Hong Chen (a1) (a2) (a3), Wei-Chen Lin (a1) (a2) (a3), Hui-Ju Wu (a2), Ya-Mei Bai (a1) (a2), Cheng-Ta Li (a1) (a2) (a3), Shih-Jen Tsai (a1) (a2) (a3), Chen-Jee Hong (a1) (a2) (a3), Pei-Chi Tu (a1) (a2) (a4), Chih-Ming Cheng (a1) (a2) (a3) and Tung-Ping Su (a1) (a2) (a4) (a3) (a5)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.